5-ASA (Aminosalicylates) in Ulcerative Colitis

What Is 5-ASA?

Drugs in This Class

• Harrison's Principles of Internal Medicine 22E, Goldman-Cecil Medicine

Indications in UC

1. Induction of remission - mild to moderate UC (oral ± topical)
2. Maintenance of remission - virtually all UC patients in remission should receive a 5-ASA preparation
3. Distal/proctosigmoid disease - topical preparations (suppositories, enemas) are highly effective

"Essentially all patients should receive maintenance therapy with a 5-ASA preparation." - Goldman-Cecil Medicine

Dosing

• Remission induction: 50-75% of mild-to-moderate UC patients improve with mesalamine doses equivalent to ≥2 g/day; dose-response continues up to at least 4.8 g/day
• Sulfasalazine: 3-6 g/day induces remission in 39-62% of patients (about twice the placebo rate)
• Higher doses = better efficacy but more side effects
• Once-daily formulations (Lialda, Apriso) improve compliance vs. 2-4 doses/day regimens
• Harrison's Principles of Internal Medicine 22E, Sleisenger & Fordtran's GI and Liver Disease

Sulfasalazine: Special Notes

• At 6-8 g/day, up to 30% of patients develop allergic reactions or intolerable side effects (headache, anorexia, nausea, vomiting)
• Hypersensitivity reactions: rash, fever, hepatitis, agranulocytosis, pneumonitis, pancreatitis, worsening colitis, reversible sperm abnormalities
• Impairs folate absorption - folic acid supplementation is required
• The sulfapyridine is merely a carrier; it is the 5-ASA component that is therapeutically active

Topical Preparations

• Rowasa enema (mesalamine): effective for mild-to-moderate distal UC (proctitis, proctosigmoiditis)
• Suppositories: for rectal disease
• Even in extensive disease, combining oral 5-ASA with topical 5-ASA gives better induction results than oral alone

Side Effects (Sulfa-Free 5-ASA Agents)

• Headache, nausea, hair loss, abdominal pain

• Renal impairment / hematuria (monitor renal function + urinalysis yearly)
• Pancreatitis
• Paradoxical worsening of colitis (5-ASA-induced colitis - can be masked by steroids and become apparent on taper)
• Hypersensitivity reactions

Position in UC Treatment Algorithm

Mild-to-Moderate UC
       ↓
5-ASA (oral ± topical) → Remission → Continue 5-ASA for maintenance
       ↓ Failure
Corticosteroids (flares only, not for maintenance)
       ↓ Persistent symptoms / Moderate-Severe
Immunomodulators (azathioprine/6-MP) or Biologics / JAK inhibitors

• 5-ASA has no proven efficacy in Crohn's disease and has largely been abandoned for Crohn's maintenance - Goodman & Gilman's Pharmacological Basis of Therapeutics
• In UC patients escalated to biologics, the additional utility of continuing 5-ASA is less well established

Key Points Summary

Mechanism of Action of 5-ASA in UC

1. NF-κB Inhibition (Primary Proposed Mechanism)

• NF-κB (nuclear factor-kappa B) is a master transcription factor that drives production of pro-inflammatory cytokines (IL-1, IL-6, TNF-α, etc.)
• 5-ASA inhibits NF-κB activity, reducing downstream cytokine production and mucosal inflammation
• This is considered the most important mechanism
• Katzung's Basic and Clinical Pharmacology 16E, Goodman & Gilman's Pharmacological Basis of Therapeutics

2. PPAR-γ Activation

• PPAR-γ (peroxisome proliferator-activated receptor gamma) is a nuclear receptor with anti-inflammatory effects
• 5-ASA activates PPAR-γ, which in turn decreases nuclear localization of NF-κB - reinforcing the above mechanism
• This is the proposed mediator of 5-ASA's therapeutic action per Harrison's
• Harrison's Principles of Internal Medicine 22E

5-ASA → PPAR-γ activation → ↓ NF-κB nuclear translocation → ↓ pro-inflammatory cytokines
5-ASA → direct NF-κB inhibition → ↓ IL-1, TNF-α, other mediators

3. Modulation of Arachidonic Acid Pathways

• Cyclooxygenase (COX) pathway: variable inhibitory effects on prostaglandin synthesis. Notably, COX inhibition is NOT the primary mechanism - unlike NSAIDs. In fact, traditional NSAIDs can worsen IBD and are contraindicated
• Lipoxygenase (LOX) pathway: inhibits the lipoxygenase pathway, reducing leukotriene production (leukotrienes are potent chemoattractants that drive neutrophil recruitment and mucosal injury)
• Katzung's Basic and Clinical Pharmacology 16E, Goodman & Gilman's

4. Free Radical Scavenging

• The inflamed colonic mucosa generates reactive oxygen species (ROS) and oxidants that damage epithelial cells
• 5-ASA acts as a scavenger of free radicals and oxidants, reducing oxidative injury to the mucosa
• Goodman & Gilman's Pharmacological Basis of Therapeutics

5. Immunomodulation

• 5-ASA inhibits cellular functions of:
  • Natural killer (NK) cells
  • Mucosal lymphocytes
  • Macrophages
• Reduces local immune activation in the colonic mucosa
• Katzung's Basic and Clinical Pharmacology 16E

Summary Table

Key Pharmacokinetic Point

• 5-ASA acts locally (topically) in the colonic lumen
• Absorbed 5-ASA is N-acetylated in the gut epithelium/liver → the acetylated form has no anti-inflammatory activity
• The azo prodrugs (sulfasalazine, balsalazide, olsalazine) rely on colonic bacterial azoreductases to cleave the azo bond and release free 5-ASA at the site of inflammation
• This explains why achieving high local drug concentration at the disease site is the key determinant of efficacy
• Katzung's Basic and Clinical Pharmacology 16E, Goodman & Gilman's Pharmacological Basis of Therapeutics